Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
Orphazyme A/SCompany announcement No. 02/2022www.orphazyme.comCompany Registration No. 32266355 Copenhagen, Denmark, January 24, 2022 – Orphazyme A/S (ORPHA.CO; ORPH) (the “Company”), a...
-
Orphazyme A/SCompany announcementNo. 01/2022Inside information Company Registration No. 32266355 Net revenue range narrowed to DKK 35 – 37 millionOperating expenses lowered to DKK 665 – 675...
-
Orphazyme A/SCompany announcementNo. 27/2021Company Registration No. 32266355 Copenhagen – December 9, 2021 – Orphazyme A/S (ORPHA.CO; ORPH or the “Company”), a late-stage biopharmaceutical...
-
Orphazyme A/SCompany announcement No. 26/2021www.orphazyme.comCompany Registration No. 32266355 Copenhagen – November 19, 2021 – Orphazyme A/S (ORPHA.CO; ORPH or the “Company”), a...
-
Orphazyme A/SCompany announcement No. 25/2021Company Registration No. 32266355 Copenhagen – November 4, 2021 – Orphazyme A/S (ORPHA.CO; ORPH or the “Company”), a late-stage biopharmaceutical...
-
Orphazyme A/SCompany announcement No. 24/2021Inside informationCompany Registration No. 32266355 Progress made in understanding potential resolution of topics outlined in Complete Response...
-
Orphazyme A/SCompany announcement No. 23/2021Company Registration No. 32266355 Copenhagen, Denmark, October 7, 2021 – Orphazyme A/S (ORPHA.CO (DK); ORPH (US)), a late-stage...
-
Orphazyme A/SCompany announcement No. 22/2021Company Registration No. 32266355 Copenhagen – October 5, 2021 – Orphazyme A/S (ORPHA.CO; ORPH), a late-stage biopharmaceutical company, today...
-
Orphazyme A/SCompany announcementNo. 21/2021CVR No.: 32266355 Copenhagen, Denmark, August 31, 2021 – Orphazyme A/S (ORPHA.CO; ORPH) (“the Company”), a late-stage biopharmaceutical company, today...
-
Orphazyme A/SInvestor news No. 08/2021Company Registration No. 32266355 Copenhagen – August 25, 2021 – Orphazyme A/S (ORPHA.CO; ORPH), a late-stage biopharmaceutical company, today announces...